On Monday, February 20th, 2023, TC BioPharm (Holdings) PLC, a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, will be hosting a special shareholder update call to discuss the latest developments in their groundbreaking therapies and treatments. At 10:00 am EST, the company will be delivering exciting news to shareholders, and all interested parties are invited to join the call and learn more about the progress being made in the world of cancer treatments. Don’t miss out on the opportunity to hear about the latest advancements in this burgeoning field!
Join us for an exciting update on the Company’s clinical trial plan for its allogeneic gamma delta therapeutic in oncology indications and get an in-depth look at our 2023 outlook. Hear from CEO Bryan Kobel and CFO Martin Thorp on our business development efforts and take part in a Q&A session after the opening remarks. Don’t miss out on this exciting opportunity for a comprehensive overview of what’s to come!
About TC BioPharm (Holdings) PLC
TC BioPharm is revolutionizing the treatment of cancer with their cutting-edge gamma-delta T cell therapies. These naturally occurring immune cells bridge the gap between the innate and adaptive immune systems, allowing them to differentiate between healthy and diseased tissue. Through their allogeneic approach, unmodified and CAR modified gamma-delta T cells are used to effectively identify, target, and eradicate both liquid and solid tumors. With human efficacy data from acute myeloid leukemia, TC BioPharm is transforming cancer treatment with their innovative approach.
TC BioPharm is revolutionizing the fight against cancer with its groundbreaking gamma-delta T cell therapies. As the first company to conduct Phase II/pivotal clinical studies in oncology, it is now conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line. With its proprietary allogenic CryoTC technology, TC BioPharm is able to provide frozen product to clinics worldwide for its Phase 2b/3 pivotal trial for OmnImmune® in the treatment of acute myeloid leukemia. This is only the beginning; the company has a robust pipeline of future indications in solid tumors and a significant IP/patent portfolio in the use of CARs with gamma-delta T cells. To ensure cost and product quality controls, TC BioPharm maintains its own manufacturing facility.